ADC THERAPEUTICS
ADC Therapeutics is a clinical-stage oncology drug discovery and development company focused on advancing highly potent and targeted antibody-drug conjugates (ADCs) for the treatment of hematological cancers and solid tumors. Their ADCs are developed using the latest-generation pyrrolobenzodiazepine (PBD) dimer technology providing a superior therapeutic index compared to first-generation PBD ADCs in preclinical studies. PBD dimers are very potent toxins that actively kill cancer cells and have a differentiated mechanism of action than warheads commonly used in other ADCs.
ADC THERAPEUTICS
Industry:
Biopharma Biotechnology Medical Therapeutics
Founded:
2011-01-01
Address:
Lausanne, Vaud, Switzerland
Country:
Switzerland
Website Url:
http://www.adctherapeutics.com
Total Employee:
251+
Status:
Active
Contact:
+1 908-731-5556
Email Addresses:
[email protected]
Total Funding:
691.55 M USD
Technology used in webpage:
Nginx Microsoft Exchange Online Amazon ReCAPTCHA Cloudflare Person Schema Cloudflare Hosting Gravatar Profiles Apple Mobile Web App Capable Cloudflare SSL
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Deerfield
Deerfield investment in Post-IPO Debt - ADC Therapeutics
Deerfield
Deerfield investment in Post-IPO Debt - ADC Therapeutics
Redmile Group
Redmile Group investment in Series E - ADC Therapeutics
Auven Therapeutics
Auven Therapeutics investment in Series E - ADC Therapeutics
AstraZeneca
AstraZeneca investment in Series E - ADC Therapeutics
Redmile Group
Redmile Group investment in Series E - ADC Therapeutics
Auven Therapeutics
Auven Therapeutics investment in Series E - ADC Therapeutics
AstraZeneca
AstraZeneca investment in Series E - ADC Therapeutics
Auven Therapeutics
Auven Therapeutics investment in Series D - ADC Therapeutics
AstraZeneca
AstraZeneca investment in Series D - ADC Therapeutics
Key Employee Changes
| Date | New article |
|---|---|
| 2022-06-13 | ADC Therapeutics Names David Gilman as Chief Business & Strategy Officer |
| 2022-05-09 | ADC Therapeutics Announces CEO Transition |
| 2020-04-21 | ADC Therapeutics Appoints Jennifer Creel as Chief Financial Officer |
Official Site Inspections
http://www.adctherapeutics.com Semrush global rank: 2.17 M Semrush visits lastest month: 9.11 K
- Host name: 141.193.213.21
- IP address: 141.193.213.21
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "ADC Therapeutics"
About Our Company – ADC Therapeutics
Applicants outside of the U.S. must qualify as a charitable organization within the country where they reside. This interactive portal allows you to: 1) provide necessary information so ADCT …See details»
ADC Therapeutics Provides Business Updates
Jan 4, 2024 We prioritized our pipeline, strengthened our organization and implemented a disciplined capital allocation model to generate cost efficiencies,” said Ameet Mallik, Chief …See details»
ADC Therapeutics - Crunchbase Company Profile
Contact Email [email protected] Phone Number +1 908-731-5556 ADC Therapeutics is a clinical-stage oncology drug discovery and development company focused on advancing highly potent and targeted antibody-drug …See details»
ADC Therapeutics - LinkedIn
ADC Therapeutics is a commercial-stage global pioneer in the field of antibody drug conjugates (ADCs). Our goal is to be a leading ADC company that transforms the lives of those impacted …See details»
ADC Therapeutics - LinkedIn
ADC Therapeutics | 18,151 followers on LinkedIn. Innovating Science. Inspiring Hope. | ADC Therapeutics is a commercial-stage global pioneer in the field of antibody drug conjugates …See details»
Investor Relations - ADC Therapeutics
Latest news for ADC Therapeutics, a commercial-stage biotechnology company improving the lives of cancer patients with its next-generation ADCsSee details»
ADC Therapeutics SA - Swiss Biotech
Abbmira therapeutics is a Basel based biotech founded by experience scientists and entrepreneurs in September 2024. Abbmira develops first-in-class small molecules to fine-tune native immunity to treat difficult-to-treat cancers and …See details»
ADC Therapeutics Releases its Inaugural Environmental, Social and ...
Feb 17, 2022 [email protected] +44 7879 627205 Amanda Hamilton ADC Therapeutics [email protected] +1 917-288-7023 EU Media Alexandre …See details»
ADC Therapeutics - Craft
Oct 29, 2024 ADC Therapeutics has 5 employees across 3 locations and $69.56 m in annual revenue in FY 2023. See insights on ADC Therapeutics including office locations, competitors, …See details»
Medical Information Hub | ADC Therapeutics | HCP Site
You are now leaving the ADC Therapeutics Medical Information Hub. ADC Therapeutics does not necessarily endorse the organization associated with this link and takes no responsibility for the content contained therein. This …See details»
Our Purpose - ADC Therapeutics
PATIENTS: Patients and their families are at the core of everything we do; they inspire our scientific creativity and innovation CHARACTER We are open, honest, trustworthy, and …See details»
ADC Therapeutics Appoints Jose Carmona as Chief Financial Officer
Dec 19, 2022 ADC Therapeutics SA (NYSE: ADCT) today announced the appointment of Jose “Pepe” Carmona as Chief Financial Officer (CFO), effective December 19, 2022. He will serve …See details»
ADC Therapeutics Reports Fourth Quarter and Year-End 2020 …
Mar 18, 2021 To access the live call, please dial 833-303-1198 (domestic) or +1-914-987-7415 (international) and provide conference ID 4985202. A live webcast of the presentation will be …See details»
Antibody Drug Conjugates Keep Growing: What You Need to Know
6 days ago In this eBook, our authors answer your legal and business questions relating to the rapid expansion of ADCs and how you and your organization can understand ADCs, whether …See details»
Careers - ADC Therapeutics
Attention: Search firms/Third-party recruitment agencies. The People team manages the recruiting for all positions at ADC Therapeutics. We will only accept résumés from a search …See details»
Our Technology - ADC Therapeutics
A novel class of PBD dimers. ADC Therapeutics’ proprietary ADCs are highly targeted drug constructs that combine monoclonal antibodies specific to surface tumor targets with a novel …See details»
ADC Therapeutics Reports First Quarter 2021 Financial Results and ...
May 6, 2021 To access the live call, please dial 888-771-4371 (domestic) or +1 847-585-4405 (international) and provide confirmation number 50158735. A live webcast of the presentation …See details»
ADC Therapeutics to Host Fourth Quarter and Year-End 2022 …
Feb 21, 2023 ADC Therapeutics SA (NYSE: ADCT) today announced that it will host a conference call and live webcast on Tuesday, February 28, 2023 at 8:30 a.m. ET to report …See details»
Antibody Drug Conjugates Clinical Development - ADC Therapeutics
ADCT-602 is an ADC composed of a monoclonal antibody that binds to CD22 conjugated to a PBD–dimer toxin. Once bound to a CD22-expressing cell, ADCT-602 is internalized into the …See details»